Market Overview

UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward

Share:
Related CRL
Earnings Scheduled For February 10, 2015
ICON Is Now A Strong Buy: Should It Be In Your Portfolio?

JP Morgan raised its rating on Charles River Laboratories (NYSE: CRL) from Neutral to Overweight and increased its price target from $40 to $42.

JP Morgan commented, "Charles River Laboratories (CRL) hosted its annual December guidance call yesterday, reiterating 2012 estimates (albeit with some EPS softness) and introducing 2013 bottom-line estimates 4-5% below consensus in light of the AstraZeneca deal (for which costs will be realized before full revenue benefits). While the news was met with disappointment, with shares -9.4%, we now see risk/reward as favorable heading into 2013 given improving fundamentals (3-5% LC growth projected vs. 1% in 2012, negative growth in 2009-2011), continued cost discipline, and importantly, a 10% free cash flow yield."

Charles River Laboratories closed at $35.65 on Wednesday.

Latest Ratings for CRL

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Feb 2015Deutsche BankMaintainsHold
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (CRL)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→